JP7747395B2 - 抗体、核酸、細胞、及び医薬 - Google Patents

抗体、核酸、細胞、及び医薬

Info

Publication number
JP7747395B2
JP7747395B2 JP2025511074A JP2025511074A JP7747395B2 JP 7747395 B2 JP7747395 B2 JP 7747395B2 JP 2025511074 A JP2025511074 A JP 2025511074A JP 2025511074 A JP2025511074 A JP 2025511074A JP 7747395 B2 JP7747395 B2 JP 7747395B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
sequence represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025511074A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024204440A1 (https=
JPWO2024204440A5 (https=
Inventor
淳 ▲高▼▲崎▼
祐司 漆畑
和世 漆畑
ゆき 林
昌子 佐々木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NB Health Labs Co Ltd
Original Assignee
NB Health Labs Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NB Health Labs Co Ltd filed Critical NB Health Labs Co Ltd
Publication of JPWO2024204440A1 publication Critical patent/JPWO2024204440A1/ja
Publication of JPWO2024204440A5 publication Critical patent/JPWO2024204440A5/ja
Priority to JP2025150483A priority Critical patent/JP2025183331A/ja
Application granted granted Critical
Publication of JP7747395B2 publication Critical patent/JP7747395B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2025511074A 2023-03-28 2024-03-27 抗体、核酸、細胞、及び医薬 Active JP7747395B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025150483A JP2025183331A (ja) 2023-03-28 2025-09-10 抗体、核酸、細胞、及び医薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023051486 2023-03-28
JP2023051486 2023-03-28
PCT/JP2024/012454 WO2024204440A1 (ja) 2023-03-28 2024-03-27 抗体、核酸、細胞、及び医薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025150483A Division JP2025183331A (ja) 2023-03-28 2025-09-10 抗体、核酸、細胞、及び医薬

Publications (3)

Publication Number Publication Date
JPWO2024204440A1 JPWO2024204440A1 (https=) 2024-10-03
JPWO2024204440A5 JPWO2024204440A5 (https=) 2025-08-05
JP7747395B2 true JP7747395B2 (ja) 2025-10-01

Family

ID=92905743

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2025511074A Active JP7747395B2 (ja) 2023-03-28 2024-03-27 抗体、核酸、細胞、及び医薬
JP2025150483A Pending JP2025183331A (ja) 2023-03-28 2025-09-10 抗体、核酸、細胞、及び医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025150483A Pending JP2025183331A (ja) 2023-03-28 2025-09-10 抗体、核酸、細胞、及び医薬

Country Status (7)

Country Link
EP (1) EP4692121A1 (https=)
JP (2) JP7747395B2 (https=)
KR (1) KR20260011663A (https=)
CN (1) CN120092019A (https=)
AU (1) AU2024247601A1 (https=)
IL (1) IL323505A (https=)
WO (1) WO2024204440A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502586A (ja) 2001-01-18 2005-01-27 アイデックス ラボラトリーズ インコーポレイテッド ＥｈｒｌｉｃｈｉａｃａｎｉｓおよびＥｈｒｌｉｃｈｉａｃｈａｆｆｅｅｎｓｉｓ抗体の検出のための組成物および方法
JP2005530484A (ja) 2002-02-07 2005-10-13 デルタ バイオテクノロジー リミテッド アルブミン融合抗血管形成ペプチド
WO2012043533A1 (ja) 2010-09-28 2012-04-05 積水化学工業株式会社 抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
JP2014530239A (ja) 2011-10-11 2014-11-17 バクシネックス インコーポレーティッド 血液脳関門透過性の調節のためのセマフォリン−４ｄ結合分子の使用
WO2020138489A1 (ja) 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
WO2022004760A1 (ja) 2020-06-30 2022-01-06 塩野義製薬株式会社 抗ｃｃｒ８抗体と化学療法剤の併用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DK0584348T3 (da) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetisk vaccine mod immundefektvirusser
US7790446B2 (en) 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
DK3334457T3 (da) 2015-08-10 2020-09-21 Pepmab B V Humaniserede anti-CCR7-receptorantistoffer
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502586A (ja) 2001-01-18 2005-01-27 アイデックス ラボラトリーズ インコーポレイテッド ＥｈｒｌｉｃｈｉａｃａｎｉｓおよびＥｈｒｌｉｃｈｉａｃｈａｆｆｅｅｎｓｉｓ抗体の検出のための組成物および方法
JP2005530484A (ja) 2002-02-07 2005-10-13 デルタ バイオテクノロジー リミテッド アルブミン融合抗血管形成ペプチド
WO2012043533A1 (ja) 2010-09-28 2012-04-05 積水化学工業株式会社 抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
JP2014530239A (ja) 2011-10-11 2014-11-17 バクシネックス インコーポレーティッド 血液脳関門透過性の調節のためのセマフォリン−４ｄ結合分子の使用
WO2020138489A1 (ja) 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
WO2022004760A1 (ja) 2020-06-30 2022-01-06 塩野義製薬株式会社 抗ｃｃｒ８抗体と化学療法剤の併用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
次世代医薬開発に向けた抗体工学の最前線，普及版，株式会社シーエムシー出版，2019年，pp. 145-148，ISBN978-4-7813-1378-8

Also Published As

Publication number Publication date
EP4692121A1 (en) 2026-02-11
KR20260011663A (ko) 2026-01-23
WO2024204440A1 (ja) 2024-10-03
JP2025183331A (ja) 2025-12-16
AU2024247601A1 (en) 2025-10-23
JPWO2024204440A1 (https=) 2024-10-03
CN120092019A (zh) 2025-06-03
IL323505A (en) 2025-11-01

Similar Documents

Publication Publication Date Title
EP3737694B1 (en) Anti-pd-1 antibodies and methods of treatment
TWI878150B (zh) 嵌合抗原及t細胞受體以及使用方法
TWI359671B (en) Cd40 antibody formulation and methods
JP2022536898A (ja) 新規ｉｌ－１５プロドラッグおよびその使用方法
CA2179196A1 (en) Method of preventing or treating disease characterized by neoplastic cells expressing cd40
EP4074732A1 (en) Fully human antibodies against ox40, method for preparing the same, and use thereof
WO2019128708A1 (zh) 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
CN106243225A (zh) 新型抗-pd-l1抗体
JP2021518138A (ja) 抗ｉｌ−２７抗体及びその使用
KR20230169135A (ko) 치료에 있어서 cd40 및 cd137에 대한 다중특이 결합제
US20210230287A1 (en) A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof
KR20010080073A (ko) 림포독소 베타 경로의 차단에 의한 바이러스-유도성 전신쇼크 및 호흡 장애의 반전
US20120201823A1 (en) April antagonists and methods of use
JP7747395B2 (ja) 抗体、核酸、細胞、及び医薬
HK40123416A (zh) 抗体、核酸、细胞和药物
CA3286179A1 (en) Antibody, nucleic acid, cell and drug
WO2022037662A1 (en) Cd40 agonistic antibody and method of use
US20240141070A1 (en) Ox40/pd-l1 bispecific antibody
TWI799959B (zh) Cd40激動劑抗體和使用方法
WO2024251160A1 (en) Anti-pvrig antibodies and uses thereof
US20240415828A1 (en) Tlr7 agonist and combinations for cancer treatment
WO2020119789A1 (en) Fully human antibodies against ox40, method for preparing the same, and use thereof
WO2020119792A1 (en) Humanized antibodies against ox40, method for preparing the same, and use thereof
BR112022006760B1 (pt) Anticorpo anti-receptor semelhante a quemerina 1 ou fragmentos de ligação ao antígeno do mesmo e usos preventivos ou terapêuticos do mesmo
HK40082317A (en) Fully human antibodies against ox40, method for preparing the same, and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250529

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250910

R150 Certificate of patent or registration of utility model

Ref document number: 7747395

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150